ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Delayed necrostatin-1s infusion attenuates cystic white matter injury in preterm fetal sheep.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Commentary on: "Delayed necrostatin-1s infusion attenuates cystic white matter injury in preterm fetal sheep."Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- The Potential Clinical Relevance of Necrosis-Necroptosis Pathways for Hypoxic-Ischaemic Encephalopathy.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe, cystic white matter injury (WMI) in preterm infants is associated with neurodevelopmental impairment. Strikingly, it often develops weeks after birth. In the present study we tested the hypothesis that necrotic programmed cell death, necroptosis, may be a key mediator of severe WMI, using the specific inhibitor necrostatin-1s (Nec-1s). Chronically instrumented preterm fetal sheep (0.7 gestation) received 25 min of hypoxia-ischaemia induced by complete umbilical cord occlusion (UCO) or sham-UCO (controls, n = 9), followed by intracerebroventricular infusion of Necrostatin-1s at 3, 8 and 13 days after UCO (UCO-Nec-1s, n = 8) or vehicle (UCO-vehicle, n = 9). Histology was obtained at 21 days after UCO. UCO-vehicle was associated with a spectrum of brain injury including diffuse WMI, and in 7/9 fetuses, generalised white matter atrophy, ventriculomegaly and/or temporal lobe cystic lesions. Necrostatin-1s infusion was associated with less severe WMI in the temporal lobe (1/8, p = 0.041), with reduced atrophy, increased density of mature oligodendrocyte cells, myelin area fraction, and reduced microgliosis but increased numbers of apoptotic cells. Interestingly, diffuse white matter injury in the parietal tracts was not affected. This study suggests that delayed, severe white matter injury after acute hypoxia-ischaemia is mediated by slowly evolving necroptosis and neuroinflammation. We speculate that Nec-1s shifts the dominant cell death pathway from necrosis toward apoptosis, allowing reduced inflammation and so preserving oligodendrocyte populations and myelination in the temporal lobe. These results suggest that necroptosis is a promising therapeutic target to mitigate severe white matter injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.